BTG.L - BTG plc

LSE - LSE Delayed Price. Currency in GBp

BTG plc

5 Fleet Place
London EC4M 7RD
United Kingdom
44 20 7575 0000
http://www.btgplc.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees1,631

Key Executives

NameTitlePayExercisedYear Born
Dr. Louise Makin MA, Ph.D.(Cantab), MBA, DBECEO & Exec. Director1.51M4.22k1961
Mr. Duncan Kennedy A.C.A., B.Sc.CFO & Director493kN/AN/A
Dr. Peter StratfordChief Technical Officer & Head of InnovationN/AN/A1967
Mr. Andy BurrowsVP of Corp. & Investor RelationsN/AN/AN/A
Dr. Paul MussendenGen. Counsel, Head of Strategic Affairs & Company Sec.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

Corporate Governance

BTG plc’s ISS Governance QualityScore as of April 1, 2019 is 9. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.